The US had the largest pharmaceutical market revenue in 2017, and is expected...
- The state of US somatic cell therapy facilities
- Tremfya approval: increasing options for psoriasis treatment
- Blockbuster immunology drugs facing patent expiry and biosimilar competition
- Takeda makes fourth offer of £44.3bn for Shire takeover
- Experts call for a review of pharma manufacturing processes
Tremfya approval: increasing options for psoriasis treatment
Johnson & Johnson’s (J&J) Tremfya (guselkumab) has recently been granted approval for the treatment of adults suffering from moderate-to-severe plaque psoriasis in Australia, Brazil, and Japan. J&J has licensed Tremfya to MorphoSys in these respective regions.
Why Choose Interlanguage for Your Translation Needs?
It is through communication that a company presents itself to the world. They are its voice and create its image, anywhere and in any language. Wherever you want to get your message across, interlanguage is by your side.
Blockbuster immunology drugs facing patent expiry and biosimilar competition
Despite the highly competitive nature of the immunology drugs market there are several well-established blockbuster drugs that dominate in terms of revenue.
Takeda makes fourth offer of £44.3bn for Shire takeover
Takeda Pharmaceutical Company has put forward a fourth offer to acquire Shire, a day after the Irish biopharmaceutical company best known for ADHD drug Adderall rejected a previous offer.
Pfizer’s Trumenba gets breakthrough status for meningococcal disease
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Pfizer’s Trumenba for meningococcal B disease in children aged between one and nine.
Experts call for a review of pharma manufacturing processes
Industry experts called for a rethink of pharma industry paradigms around manufacturing orphan and cell products at DCAT Week 2018, which took place in New York City last month.
Pfizer funds CreakyJoints’ initiative for shared decision making in rheumatoid arthritis
In a landmark moment for rheumatoid arthritis (RA) treatment, Pfizer has joined forces with CreakyJoints, an online patient advocacy group, in an initiative to improve shared decision making about treatment options.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.